SAFC Pharma's St. Louis HPAPI Conjugates Facility Receives SafeBridge Cer...(tion and evaluation (3) hazard controls ...),Health

The new SafeBridge certification of the St. Louis HPAPI suite adds to SAFC investments totaling $75 million during the past 18 months to expand its HPAPI capacity. Those include a $4.5 million project to add a cGMP pilot plant and kilo-lab capacity at the Madison facility, completed in early 2008; a $29 million investment to expand bacterial and fungal fermentation derived HPAPI capacity at Jerusalem, Israel, due for completion in early 2010; and a $30 million investment to build a new commercial-scale HPAPI facility at Madison, due to be completed by year-end 2009.

About SAFC: SAFC(R) is the custom manufacturing and services group within Sigma-Aldrich that focuses on high-purity inorganics for high technology applications, cell culture products and services for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials. SAFC has four business segments - SAFC Pharma(R), SAFC Supply Solutions(R), SAFC Biosciences(R), and SAFC Hitech(R)- and had annual sales of over $600 million in 2008. SAFC is considered a top 10 fine chemical company. For more information about SAFC, visit www.safcglobal.com.

About SAFC Pharma(R): SAFC Pharma is a complete pipeline partner for the development and cGMP custom manufacturing of complex small-molecule APIs and biologic drug products. It combines world-class project management and chemistry support for all stages of the drug discovery and development process from research and discovery, through pre-clinical and clinical dev
'/>"/>